1.2 | This legal opinion (“Opinion”) is issued in connection with the public offer and sale by the Issuer (“Offering”) of (i) EUR 250,000,000 aggregate principal amount of floating rate senior notes due 2021 (“Floating Rate Notes”), EUR 750,000,000 aggregate principal amount of 0.00 % senior notes due 2022 (“2022 Notes”), EUR 1,000,000,000 aggregate principal amount of 0.25 % senior notes due 2025 (“2025 Notes”), EUR 1,000,000,000 aggregate principal amount of 1.00 % senior notes due 2031 (“2031 Notes”) and EUR 1,000,000 aggregate principal amount of 1.50 % senior notes due 2039 (“2039 Notes”), and EUR 1,000,000,000 aggregate principal amount of 1.75 % senior notes due 2049 (“2049 Notes”, and together with the Floating Rate Notes, the 2022 Notes, the 2025 Notes, the 2031 Notes and the 2039 Notes, the“Fixed Rate Notes”). The Floating Rate Notes and the Fixed Rate Notes are referred to collectively as the“Notes” pursuant to the terms of a New York law governed underwriting agreement, dated June 25, 2019 entered into by and among the Issuer as issuer, Medtronic Public Limited Company (“Medtronic PLC”) and Medtronic, Inc. and the underwriters as listed in Schedule I of the Underwriting Agreement (“Underwriting Agreement”). The Floating Rate Notes are further issuances of, fully fungible with, rank equally in right of payment with, and form a single series with the EUR 500,000,000 aggregate principal amount of Floating Rate Notes due 2021 issued by the Issuer on March 7, 2019. The Floating Rate Notes will be issued pursuant to the Senior Indenture |